Na Septemba 8, 2025, InnoCare Pharma kwupụtara na Health Sciences Authority (HSA) nke Singapore akwadola HIBRUKA (orelabrutinib) maka ọgwụgwọ nke ndị okenye nwere lymphoma mpaghara marginal refractory marginal (R/R MZL).
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Ọrịa lymphoma nke dị n'akụkụ aka nri (MZL) bụ ọrịa lymphoma nke na-abụghị nke Hodgkin (NHL) nke na-emetụtakarị ndị agadi na ndị agadi. Ọrịa MZL na-amụba kwa afọ n'ụwa niile. Mgbe ọgwụgwọ mbụ gasịrị, ndị ọrịa nwere R/R MZL enweghị nhọrọ ọgwụgwọ dị irè.
N'ọnwa Eprel afọ 2025, orelabrutinib natara nkwado na China maka ọgwụgwọ mbụ nke ndị ọrịa nwere ọrịa leukemia lymphocytic na-adịghị ala ala (CLL) / obere lymphoma lymphocytic (SLL). A nabatakwara Orelabrutinib maka ọgwụgwọ ihe mgbaàmà atọ ndị ọzọ na China, gụnyere CLL/SLL nke na-alaghachi azụ na nke na-adịghị ike (R/R), r/r mantle cell lymphoma (R/R MCL) na r/r marginal zone lymphoma (R/R MZL), nke a niile ekpuchila na Ndepụta Ọgwụ Mweghachi Mba China.
Ọrụ, Nchekwa, na Ezi Uche nke Orelabrutinib Plus Obinutuzumab n'Ọgwụgwọ Sistemụ - Lymphoma Naive Marginal Zone: Ọmụmụ Ndị otu a na-atụ anya gosiri na n'ọmụmụ ihe ahụ dum na n'oge ọgwụgwọ induction, ọnụego nzaghachi zuru oke (ORR) bụ 100%. Ndị ọrịa atọ nwere mmeghachi omume akụkụ (PR) mgbe ọgwụgwọ induction gasịrị nwetara nzaghachi zuru oke (CR) n'oge mmezi.
Nnyocha ADCC gosiri na orelabrutinib na usoro obinutuzumab kpalitere nzaghachi ADCC kachasị arụ ọrụ na ahịrị mkpụrụ ndụ TMD-8 na REC-1.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Oge ozi: Sep-09-2025